-+ 0.00%
-+ 0.00%
-+ 0.00%

Viracta Therapeutics Plans To Close Its Ongoing Pivotal Phase 2 Clinical Trial Of Nana-val In Relapsed/Refractory EBV + Lymphomas

Benzinga·12/26/2024 21:31:59
Listen to the news

The company emphasized that its decision to voluntarily close the trial is not the result of any new safety finding.